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Abstract 
Background: Curcumin (Ccm) has shown immense potential as an antimalarial agent; however its low solubility and 
less bioavailability attenuate the in vivo efficacy of this potent compound. In order to increase Ccm’s bioavailability, 
a number of organic/inorganic polymer based nanoparticles have been investigated. However, most of the present 
day nano based delivery systems pose a conundrum with respect to their complex synthesis procedures, poor in vivo 
stability and toxicity issues. Peptides due to their high biocompatibility could act as excellent materials for the syn-
thesis of nanoparticulate drug delivery systems. Here, we have investigated dehydrophenylalanine (ΔPhe) di-peptide 
based self-assembled nanoparticles for the efficient delivery of Ccm as an antimalarial agent. The self-assembly and 
curcumin loading capacity of different ΔPhe dipeptides, phenylalanine–α,β-dehydrophenylalanine (FΔF), arginine-α,β-
dehydrophenylalanine (RΔF), valine-α,β-dehydrophenylalanine (VΔF) and methonine-α,β-dehydrophenylalanine (MΔF) 
were investigated for achieving enhanced and effective delivery of the compound for potential anti-malarial therapy.
Results: FΔF, RΔF, VΔF and MΔF peptides formed different types of nanoparticles like nanotubes and nanovesicles 
under similar assembling conditions. Out of these, F∆F nanotubes showed maximum curcumin loading capacity of 
almost 68 % W/W. Ccm loaded F∆F nanotubes (Ccm-F∆F) showed comparatively higher (IC50, 3.0 µM) inhibition of 
Plasmodium falciparum (Indo strain) as compared to free Ccm (IC50, 13 µM). Ccm-F∆F nano formulation further demon-
strated higher inhibition of parasite growth in malaria infected mice as compared to free Ccm. The dipeptide nano-
particles were highly biocompatible and didn’t show any toxic effect on mammalian cell lines and normal blood cells.
Conclusion: This work provides a proof of principle of using highly biocompatible short peptide based nanoparticles 
for entrapment and in vivo delivery of Ccm leading to an enhancement in its efficacy as an antimalarial agent.
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Background
Malaria, one of the most devastating infectious dis-
ease, affects almost half of the global population [1]. In 
humans, malaria is caused by a unicellular organism, 
the Plasmodium parasite and is transmitted through 
the female Anopheles mosquito. Plasmodium para-
site has many different species, of which P. falciparum 
accounts for most human deaths mostly in sub Saharan 
Africa. Malaria symptoms are generally associated with 
headache, chills, fever and vomiting, which are initially 
mild and hence difficult to distinguish as malaria. If 
appropriate treatment is not administered within 24 h, P. 
falciparum infection can progress and cause severe anae-
mia, respiratory distress or cerebral malaria which often 
leads to death [2].
In the present scenario, few drugs like chloroquine, 
sulfadoxine–pyrimethamine (SP), artemisinin and its 
derivatives are the only available effective treatment 
modalities for malaria. However, drug resistance and tox-
icity to most of the available drugs like chloroquine and 
SP poses a serious and growing challenge to treat malaria 
[3–7] Artemisinin and its combinations with other drugs 
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(ACT’s) have been successfully used to treat malaria, but 
recent reports of resistance to artemisinin particularly in 
many Southeast Asian countries has made the situation 
grim [8, 9]. Therefore, there is an urgent need to develop 
new drugs and new treatment strategies to cure malaria. 
Several chemical compounds either synthetic or isolated 
from natural sources are being actively investigated for 
their antimalarial activity [10–14] and although there 
seems to be a fairly good number of anti-malarial mol-
ecules in pipeline, the situation is far from satisfactory. 
Curcumin (Ccm) isolated from the rhizomes of curcuma 
longa (turmeric), has been shown to possess strong anti-
malarial activity in several studies. It has been shown to 
disrupt microtubules, inhibit histone acetylation and 
generate reactive oxygen species to kill the parasite [15–
17]. However, certain features like poor absorption, rapid 
metabolism and fast elimination from the body lead to its 
low bioavailability and limit its therapeutic effects as an 
anti-malarial agent [18].
Nanoparticles owing to their small size demonstrate 
special features like protection of drugs from non-spe-
cific degradation, increment in drug half-life, prevention 
of drug resistance, increased bioavailability, site specific 
delivery of therapeutic compounds and reduced toxicity 
to other body parts etc [19–21]. A number of organic/
inorganic polymer based nanoparticles have been devel-
oped as efficient drug delivery systems and many of these 
have also been used for the entrapment and delivery of 
Ccm [22–24]. However, most of these nanoparticles 
demonstrate low biocompatibility, which prevent their 
direct applications in human targets [25–29].
Moreover, the complex way of synthesis of these nano-
particles poses hurdles in their large scale synthesis and 
commercialization. In this context nanoparticles based 
on biocompatible building blocks offer an attractive alter-
native and in recent years a number of peptide based 
nanoparticles have been reported [30–33]. But, on the 
other hand peptide based systems also have an inherent 
drawback in that they are susceptible to enzymatic deg-
radation leading to their short half-life in in  vivo situa-
tions. In this regard short peptide based nanoparticles; 
particularly those containing unnatural amino acids may 
offer an attractive alternate solution. In this direction we 
have used α, β-dehydroamino acids in designing short 
peptides which can self-assemble into stable and highly 
biocompatible nanostructures and as potential biomol-
ecule delivery system [34–36].
Here, we report synthesis and characterization of α,β-
dehydrophenylalanine containing self-assembling and 
biocompatible dipeptide nanoparticles (DNPs) and their 
potential as drug delivery systems for hydrophobic drugs 
like Ccm. Results of both in  vitro and in  vivo studies 
demonstrated enhanced antimalarial activity with DNPs 
loaded Ccm in comparison to the free drug. The unique 
one step synthesis, long term stability of these DNPs and 
their biocompatibility make them highly effective plat-
forms for further development as efficient carriers for 
hydrophobic drug like Ccm.
Results and discussion
Synthesis and characterisation of the DNPs
Four different dipeptides used in the present study were 
synthesised using solution phase peptide synthesis meth-
ods. The peptides were purified by reverse phase high 
performance liquid chromatography (RPHPLC) and 
characterised using mass spectrometry (Table 1).
For initiating self-assembly, the peptides (2  mg each 
in case of R∆F, V∆F and M∆F and 0.5  mg in case of 
F∆F) were first dissolved in 100  µl of isopropanol fol-
lowed by addition of 1  ml of water. The samples were 
further incubated for 5–6  h at room temperature. For-
mation and properties of the DNPs were then studied 
using dynamic light scattering (DLS) and transmission 
electron microscopy (TEM). From light scattering stud-
ies, it was observed that all the four dipeptides could 
form monodispersed nanostructures with low polydis-
persity indices. RΔF formed nanoparticles with hydro-
dynamic diameter of 304 ± 20 nm, whereas MΔF, VΔF, 
and FΔF formed nanoparticles of hydrodynamic diam-
eter of 200 ± 15, 220 ± 25 and 980 ± 45 nm respectively 
(Table 2). It is likely that dipeptides self assembled under 
these conditions by virtue of nanoprecipitation mecha-
nism, where isopropanol acted as a solvent and water as 
an anti-solvent [37]. Hydration with water perhaps ren-
ders the hydrophobic moieties of the peptides insoluble, 
triggering the self-assembly process. Assembly could be 
stabilized by non-covalent interactions like hydrogen 
bonding, hydrophobic interactions, van der Waals and 
electrostatic interactions as well as π–π stacking inter-
actions between the aromatic residues [38, 39]. Head 
to tail hydrogen bonding and π–π stacking interactions 
responsible for stabilizing the assembled nanotubes were 
observed in crystal structure of FΔF [34]. This is in line 
with the self-assembly of Phe–Phe, where the dipeptide 
was first dissolved in an organic solvent like in hexafluor-
oisopropanol at a concentration of 100 mg/ml and then 
Table 1 Characterization of  dipeptides: HPLC retention 
time and mass of FΔF, RΔF, MΔF and VΔF dipeptide






1 RΔF 28.0 319.39 320.181
2 MΔF 29.5 294.407 295.118
3 VΔF 34.5 262.341 263.342
4 FΔF 24.0 310.38 311.140
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diluted with water to a final concentration of 0.5 mg/ml 
to form nanotubes [40].
Transmission electron microscop (TEM) was used to 
investigate the morphological details of the nanoparti-
cles. It was observed that RΔF assembled into vesicular 
structures with mean diameter of 62 nm. M∆F and V∆F 
also formed vesicular structures with mean diameter of 
40 and 55 nm respectively. However, similar to our ear-
lier studies [41] the dipeptide F∆F under these conditions 
self-assembled into tubular structures with mean diam-
eter of 25 nm and length in microns (Fig. 1a–d). The final 
properties of the peptide assemblies, including their size, 
shape are governed by a delicate balance of the intermo-
lecular interactions mentioned above and hence different 
dipeptides form different types of nanostructures. Ear-
lier studies have also demonstrated similar phenomenon 
where a slight change in peptide sequence resulted in the 
formation of nanostructures of varied morphologies and 
dimensions [42, 43].
In vitro cytotoxicity and haemolytic assay
Nanoparticle based delivery systems offer several advan-
tages like site-specific delivery of entrapped molecules, 
yet toxicity of nanomaterial towards healthy cells remains 
an important concern [19, 44]. In  vitro cytotoxicity of 
void DNPs was assessed in mouse fibroblasts (L929) cul-
tured in RPMI medium. Cells were seeded at a density of 
1 ×  104 cells per well in 200  µl of cell growth medium 
and exposed to increasing concentrations of DNPs 
(0–4000  µM) for period of 24  h, followed by measure-
ment of cell viability using MTT assay. The 50 % cytotox-
icity concentration (CC50) of these DNPs were found to 
be 800, 1160, 2680 and 3100 μM for VΔF, FΔF, MΔF and 
RΔF respectively (Fig. 2a).
Cytotoxicity was also assessed with lactate dehydro-
genase (LDH) release assay. LDH is a soluble cytosolic 
enzyme that is released into the culture medium fol-
lowing loss of membrane integrity resulting from either 
apoptosis or necrosis. LDH activity, therefore, can be 
used as an indicator of cell membrane integrity and 
serves as a general mean to assess cytotoxicity resulting 
from chemical compounds or environmental toxic fac-
tors. L929 cells treated with the DNPs at a concentration 
of 50 μM, exhibited similar release of LDH to the media 
as untreated cells, suggesting that these DNPs are safe for 
in vivo applications (Fig. 2b).
Nanoformulations delivered into the body, will finally 
enter the circulation and may adversely affect the red 
blood cells (RBCs). Hemolysis (destruction of red blood 
cells) can lead to anemia, jaundice and other pathologi-
cal conditions; therefore the hemolytic potential of all 
intravenously administered pharmaceuticals must be 
evaluated. Measuring the percentage of hemolysis is 
an appropriate way to detect the toxicity of a test com-
pound towards RBCs [45, 46]. We performed hemolytic 
assays for all four DNPs at three different concentrations 
(10, 20 and 50  µM) and found that none of the DNPs 
were hemolytic even at 50  µM concentration (Fig.  2c). 
Results of cytotoxicity and hemolysis assay suggested 
that these DNPs are highly biocompatible and therefore 
safe for biological applications, including intra venous 
drug delivery.
Loading the DNPs with Ccm
Dissolution and entrapment of highly hydrophobic 
drugs like Ccm inside nano or micro-carriers requires 
strong nonaqueous solvents and it is generally difficult 
to remove the solvent from the final drug-nano formula-
tion, which is a concern in their potential application in 
in vivo drug delivery [47, 48]. Dipeptide based nanopar-
ticles reported here are prepared under largely aqueous 
environment endowing them the suitability for poten-
tial in  vivo applications. After characterizing the DNPs, 
we next investigated their ability to load Ccm following 
the post loading method. Ccm was dissolved in metha-
nol (10  mg/ml) and DNPs were incubated with three 
different concentrations of Ccm (1, 2 and 3 mg of Ccm/
ml of DNPs) for 72  h. Unbound Ccm was removed by 
filtration (50  kDa Amicon® Ultra-0.5) followed by lyo-
phylisation of nanoforumlation. Optimum loading was 
observed at a Ccm concentration of 3  mg/ml. At this 
concentration, Ccm loading was found to be 68 ± 0.07 % 
(w/w) in F∆F nanotubes, ~8 % (w/w) for VΔF nanovesi-
cles, ~12 % (w/w) for MΔF nanovesicles and ~14 % (w/w) 
for RΔF nanovesicles (Table  3). The relatively higher 
loading observed in case of FΔF could be attributed to 
optimum hydrophobic interactions between the drug 
molecules and the peptide nanotubes and also possibly 
to enhanced π–π interactions between planar aromatic 
structure of the drug and the two aromatic rings in FΔF. 
Since FΔF turned out to be most efficient in entrapping 
Ccm, this combination was taken up for further investi-
gations. Ccm-FΔF analyzed using TEM demonstrated 
that Ccm loading did not disturb the overall morphol-
ogy of the DNPs (Fig.  1e). lyophilised Ccm loaded FΔF 
nanotubes (Ccm-FΔF) were resupended in water and this 
Table 2 Characterization of  DNPs: hydrodynamic diame-
ters and polydispersity indices of dipeptide nanoparticles




1 RΔF 304 ± 20 0.07
2 MΔF 200 ± 15 0.12
3 VΔF 220 ± 25 0.22
4 FΔF 980 ± 45 0.36
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suspension in colloidal form was used for drug release, 
stability as well as for in vitro and in vivo efficacy studies.
Release of Ccm from Ccm‑FΔF
Ccm release from the Ccm-FΔF was followed by using 
dialysis membrane bag method [49, 50]. Release was 
monitored for a period of 96 h in a mixture of methanol–
water (1:1 v/v) as dissolution media. Methanol–water 
(1:1 v/v) was used as a release media because of appro-
priate solubility of Ccm in this media which would main-
tain a sink like condition for the drug release [51]. Release 
patterns of both free and nanoparticle bound Ccm are 
shown in Fig.  3. Free Ccm showed a quicker release 
(55  ±  2.8  %) from the dialysis membrane as compared 
to Ccm-FΔF (30 ±  2.5  %) over a period of 6  h. Where 
almost 90 % of free Ccm was released from the dialysis 
membrane in just 9–10  h, the Ccm-FΔF nanoformula-
tions took almost 90 h to release 80 % of the initial loaded 
Ccm concentration. Similar release pattern was also 
observed earlier in case of Ccm loaded in MAX8 peptide 
hydrogel [52].
Stability of Ccm‑FΔF nanoparticles
Use of nanoparticle based systems as possible drug deliv-
ery agents necessitates them to be stable over a period of 
time [53]. We assessed the stability of Ccm-F∆F nanopar-
ticles towards various parameters which include, mor-
phological stability using TEM imaging, retention of drug 
content and drug release behavior. After being stored for 
different time periods (1, 7, 14, 28 and 56 and 90  days) 
at room temperature (25 ± 2 °C), Ccm-F∆F were resus-
pended in water (1  mg/ml) and observed under TEM. 
Results demonstrated that the morphology of Ccm-FΔF 
nanoparticles were intact even after 90 days of storage at 
room temperature ((25 ± 2 °C) Fig. 4).
Stability of drug content in the nanoparicles was 
also proved by determining Ccm stability, content and 
release from Ccm-F∆F over the period of storage. Due 
to its polyphenolic structure, Ccm shows inherent fluo-
rescence properties, which also depends on the mole-
cules local environment [54]. Thus, the stability of Ccm 
inside the nanoparticles was determined by measur-
ing its fluorescence properties. Fluorescence spectra 
Fig. 1 Transmission electron micrographs of DNPs: TEM image of a F∆F, showing the formation of tubular structure with mean diameter of 25 nm 
and length in microns, b M∆F, demonstrating the formation of vesicular structures with mean diameter of 40 nm c V∆F, showing the formation of 
vesicular structures with mean diameter of 55 nm, d RΔF demonstrating the formation of vesicular structures with mean diameter of 62 nm and  
e Ccm-F∆F showing dense tubular structures
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of a methanol: water solution (1:1; v/v) of Ccm taken at 
an excitation wavelength of 425  nm showed an emis-
sion peak at 545  nm. An aqueous methanolic solution 
of Ccm-FΔF at two time points (day 1 and 90) showed a 
similar emission pattern, suggesting that entrapment in 
FΔF DNPs had no effect on the photophysical properties 
of Ccm and also the drug is stable inside the DNPs for a 
period of 90  days (Fig.  5i). We next estimated the Ccm 
content in the DNPs after being stored at the room tem-
perature (25 ±  2  °C) for a period of 90  days and found 
that there was no significant change in the Ccm con-
tent of the nanoformulations during these time period 
(Fig.  5ii). Further, Ccm-FΔF nanoformulations stored at 
room temperature (25 ± 2 °C) for 90 days showed release 
patterns similar to that found on day 1 (Fig.  3). These 
results taken together demonstrate long term stability of 
the Ccm-FΔF nanoparticles as well as the drug, Ccm, in 
the DNPs.
In vitro antimalarial activity
Antimalarial activity of Ccm has been reported previ-
ously [16, 17]. However, its poor aqueous solubility and 
hence low bioavailability has limited its use as an anti-
malarial agent. We have addressed this issue by loading 
Ccm in the DNPs and evaluated their activity in parasite 
culture. Ccm-F∆F showed significant growth inhibi-
tion against chloroquine resistant P.falciparum (indo) in 
comparison with the free drug and nanoparticles alone 
(Fig.  6). The IC50 value of Ccm-F∆F nanoparticles and 
free Ccm against P. falciparum was found to be 3.0 and 
13  µM respectively. Thus, the drug loaded nanoparti-
cles demonstrated almost fourfold reduction in the IC50 
concentration as compared to native Ccm. Enhancement 
in anti-malarial activity was also found in case of Ccm 
loaded in chitosan nanoparticles [55].
In vivo antimalarial activity of Ccm‑FΔF
In vivo antimalarial efficacy of Ccm-FΔF nanoparticles 
and free Ccm in P. berghei (ANKA) infected BALB/c 
Fig. 2 In vitro cytotoxicity and haemolytic assay: cell toxicity was assessed using a MTT assay. L929 cells were treated with different concentra-
tions i.e., from 0 to 4000 µM of the DNPs for 24 h. Viability was expressed as the percentage of media control. b LDH release assay: cells treated with 
50 µM of DNPs showed almost similar release of LDH like PBS treated cells. Cells treated with DMSO as positive control showed the maximum LDH 
release. c Percentage haemolysis at three different concentrations. None of the DNPs showed haemolytic activity. Triton X-100 taken as a positive 
control showed 100 % haemolysis
Table 3 Percentage loading of  curcumin in  DNPs at  dif-
ferent concentrations: out  of the four DNPs, FΔF showed 
highest loading at a curcumin concentration of 3 mg/ml
Curcumin (mg/ml) % loading
FΔF MΔF VΔF RΔF
1 42 ± 0.63 8 ± 0.33 6 ± 0.68 10 ± 0.72
2 55 ± 0.23 10 ± 0.13 7 ± 0.55 12 ± 0.12
3 68 ± 0.07 12 ± 0.66 8 ± 0.35 14 ± 0.76
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mice is presented in Figs.  7 and 8. An analysis of the 
survival graph of mice and parasite growth count analy-
sis revealed differences between the control groups ver-
sus the groups treated with free and entrapped Ccm. In 
this assay, all mice in the control group treated with PBS, 
and FΔF, died with high parasitemia between day 10 and 
14. In the group of mice treated with Ccm alone also 
parasitemia  rose at the same rate as the control group, 
although mice in the group survived somewhat longer 
than the PBS control group, all mice in this group died 
by day 18. In mice treated with Ccm-FΔF, there was a 
significant reduction in the growth of parasitemia. Ani-
mals administered with Ccm-FΔF showed an increased 
life span and enhanced survival rate as compared to 
those treated with Ccm alone. Earlier studies have shown 
that curcuminoids have beneficial therapeutic effects 
only in their active form [56, 57]. The attenuated effect 
of free Ccm might be due to immediate degradation of 
curcuminoids to inactive metabolic products (trans-6-
(4-hydroxy-3-methoxyphenyl)-2,4-dioxo-5-hexenal, van-
illin, ferulic acid and feruloyl methane) in the blood. The 
slow release mechanism of Ccm from the nanoparticles 
as evident from the in vitro release studies was expected 
to maintain an effective concentration of Ccm in the 
blood as compared to free Ccm leading to an enhance-
ment in parasite killing efficacy.
Conclusions
Here, we have described the synthesis and characterisa-
tion of Ccm loaded self-assembled DNPs, which can be 
easily prepared under relatively mild aqueous conditions. 
These DNPs are non-cytotoxic and non-haemolytic. Ccm 
loaded DNPs (Ccm-FΔF) showed much higher activity 
of Ccm in comparison to free Ccm under both in  vitro 
and in vivo conditions. Such short peptide based delivery 
systems may have potential for further development for 
applications in the field of malarial drug delivery.
Methods
N-methyl morpholine (NMM), 1,1,1,3,3,3-hexafluoro-
2-propanol (HFIP), trifluoroacetic acid (TFA), Ccm 
(diferuloyl methane), isobutyl chloroformate (IBCF), 
methanol and DL-threo-β-Phenylserine was purchased 
from Sigma–Aldrich (St. Louis, MO, USA). N-[(tert-
butoxy)carbonyl]-l-methionine, l-phenylalanine, Anhy-
drous sodium sulfate and citric acid were obtained from 
Novabiochem (Merck, Darmstadt, Germany). Diethyl 
ether, Sodium acetate, tetrahydrofuran (THF), ethyl ace-
tate, and acetonitrile were purchased from Spectrochem 
Pvt Ltd (Mumbai, India). Cell lines L-929 (Mouse fibro-
blast) from ATCC (Manassas, VA). Chloroquine resist-
ant strains of P. falciparum (Indo) were obtained and 
grown in human O+ erythrocytes at 3  % hematocrit in 
Fig. 3 Release of curcumin from Ccm-FΔF: in vitro curcumin release from Ccm-FΔF nanoformulations, stored at room temperature for different 
time points (day 1, 14 and 90) in methanol: water (1:1 v/v). Curcumin content was estimated using (UV–Vis) spectrophotometer at a wavelength of 
425 nm. (n = 3), error bar represent ± standard deviations
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a complete medium (RPMI 1640 medium supplemented 
with 25 mM HEPES, pH 7.5, 25 mM sodium bicarbonate, 
50 mg/liter hypoxanthine,0.5 % Albumax II, and 40 µg/ml 
gentamicin sulfate). Cultures were maintained at 37 °C in 
a gas mixture of 5 % CO2 and 3 % O2. All other chemicals 
and buffers were of the highest grade available.
Synthesis of nanostructure forming dipeptides
Synthesis of phenylalanine-dehydrophenylalanine (FΔF), 
was carried out using solution phase peptide synthe-
sis. In brief, Boc-Phe-OH (10  mM; 2.48  g) was dis-
solved in anhydrous THF, the solution was chilled to 
−20  °C in an ice-salt mixture and kept for stirring for 
10  min. IBCF (10  mM; 1.39  ml) was then added to the 
solution followed by NMM (10  mM; 1.31  ml). After 
stirring for 20  min, a pre chilled solution of DL-threo-
β-phenylserine (11  mM; 1.98  g) and sodium hydrox-
ide (11 mM; 0.44 g) in MQ-water were added. Reaction 
mixture was stirred over night at room temperature and 
concentrated in rota evaporator. The residual solution 
was acidified with chilled concentrated solution of citric 
acid. Extraction of intermediate product (Boc-Phe-DL-
threo-β-phenylserine) was done by using ethyl acetate. 
Ethyl acetate solution was then dried by passing through 
anhydrous sodium sulphate followed by drying in rota 
vapour. Dried Boc-Phe-DL-threo-β-phenyl serine were 
solubilised in acetic anhydride (100 ml) and mixed with 
sodium acetate (6.5  mM; 1.16  g) and stirred for 36  h. 
Reaction was stopped by adding crushed ice and filtered 
the precipitate using grade four filtered funnel. Filtrate 
was washed thrice with cold water and dried in desicca-
tors. Obtained powder (Boc-Phe-ΔPhe-azalactone) was 
dissolved in methanol and stirred with 1.5 equivalent of 
1 N NaOH for 4 h. Resulting solution was concentrated 
on rota vapour and extracted with ethyl acetate. Peptide 
was de protected by treating the compound with anhy-
drous tetrahydrofuran (THF) and purified on reverse 
phase HPLC(LC-6 AD, Shimadzu, Kyoto, Japan) using 
C18 column (Phenomenex, Hyderabad, India, C18, 5 μm, 
id 250  ×  4.6  mm) in acetonenitrile (0.1  % TFA)-water 
(0.1 % TFA) with 2 % linear gradient. Other di-peptides 
used for this study were synthesised using similar method 
Fig. 4 Stability of Ccm-FΔF nanotubes: TEM photographs of curcumin loaded nanotubes at different time points. a–f represent images taken after 
1,7,14, 28, 56 and 90 days of incubation at room temperature (25 ± 2 °C). Results demonstrated the stability of curcumin loaded nanotubes over the 
entire incubation period of 90 days
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as described above. The mass of peptide were obtained 
by using mass spectrometer (AppliedBiosystemsQStar 
(Q-TOF), Ontario, Canada).
Preparation and characterization of DNPs
Nanostructure of different dipeptides was prepared 
by dissolving the dipeptides (2 mg each in case of V∆F, 
M∆F, R∆F and 0.5  mg in case of F∆F) in 100  μl of iso-
propanol. While MΔF and RΔF were found to be soluble 
in isopropanol, VΔF and FΔF were only soluble when 
heated. Self-assembly of these dipeptides was initiated by 
addition of 1 ml of water to the isopropanol solution of 
the dipeptides followed by incubation for 4–6 h at room 
temperature prior to use.
Dynamic light scattering studies
DLS was used to determine the particle size and size dis-
tribution of these self-assembled nanoparticles. Light scat-
tering studies were performed on Zetasizer NanoZS90 
(Malvern Ltd, Malvern, UK) at an angle of 90° using a 
633  nm laser. All these experiments were performed at 
room temperature and under dust free environment.
Fig. 5 Fluorescence emission spectra of curcumin: i fluorescence spectra of both curcumin (A) and Ccm-FΔF at two different points, (B) at 1 day 
and (C) after 90 days, in aqueous solution of methanol (1:1, v/v) at an excitation wavelength of 425 nm. ii Amount of curumin present in Ccm-
FΔF nano-formulations during the incubation period. Curcumin content was determined at three different time points (1, 14 and 90 days). It was 
observed that the curcumin concentration inside the nanotubes remained almost constant even after 90 days of storage depicting the stability of 
the drug inside the nanotubes
Fig. 6 Malaria parasite (Pf indo) inhibition assays under in vitro conditions: Curcumin entrapped in nanotubes inhibited the growth of chloroquine-
resistant P.falciparum (Pf indo) in culture, more efficiently (IC50, 3 µM) than free curcumin (IC50, 13 µM). Void nanotubes (F∆F) did not show any inhibi-
tory effect
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Structural characterization of DNPs using transmission 
electron microscopy
Transmission electron microscopy of DNPs was carried 
out using uranyl acetate negative staining method. In 
brief, DNPs were loaded by adsorbing a drop of DNPs on 
a 200 mesh 3 mm carbon supported nickel grid. Staining 
of loaded DNPs was done by incubating the loaded grid 
with 1 % uranyl acetate for 30 s at room temperature. The 
Fig. 7 Survival graph of P. bergi-infected mice treated with different groups. Most of the mice in the group treated with PBS and FΔF died with high 
parasitemia between 10 and 14 days of infection. Mice treated with free Ccm showed increased life span but died earlier than those treated with 
Ccm-FΔF
Fig. 8 Percentage parasitemia of different groups of mice: Mice treated with intra-peritoneal injection of the nanoformulations. a PBS and b FΔF 
treated group. These groups showed increase in parasitemia with time killing all the animals. c Ccm (50 mg/kg BW of curcumin) treated group, 
where parasitemia rose slowly and mice survived for the longer time as compared to the PBS control group. d Mice treated with Ccm-FΔF (equiva-
lent to 50 mg/kg BW of curcumin) showed significant decrease in parasitemia and increase in life span
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loaded grid was air dried at room temperature prior to be 
observed under the microscope. Samples were observed 
under a transmission electron microscope (TEM) (Tec-
nai 120 BioTWIN, FEI Netherlands) operated at 120 kV. 
The image was captured using a Megaview II digital cam-
era and analysis was carried out using Analysis II (Meg-
aview, SIS, Germany) the iTem software package.
In vitro cytotoxicity assays
Cell viability assay (MTT assay)
Cytotoxic effect of void DNPs was assessed by the 
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dye conversion assay. MTT is a yel-
low tetrazole that gets converted into a purple insolu-
ble formazan because of the mitochondrial reductase 
enzyme present in live cells. The Mouse fibroblast cell 
line (L929) was purchased from ATCC and maintained 
in Roswell Park Memorial Institute (RPMI) cell growth 
medium supplemented with 10  % heat inactivated fetal 
bovine serum (HI-FBS) at 37  °C in a 5  % CO2 incuba-
tor. Following two passages, the cells were harvested 
and seeded at a density of 1 × 104 cells/well in 200-μl of 
complete cell culture growth medium, in a 96-well cell 
culture plate. After 12 h of incubation, the cultured cells 
were treated with different concentrations (0–4000 µM) 
of DNPs and incubated in the same incubator for another 
24  h. Media was then replaced with fresh media after 
24  h and cells were treated with 20  µl (5.0  mg/ml in 
PBS) of MTT (filter sterilised using 0.2 µ filter) for 4 h. 
Once the incubation period was over, media from each 
well was removed and 100 μl of DMSO was added into 
each well to dissolve purple formazan which is formed in 
live cells. The absorbance of formazan was measured at 
570 nm using a microplate reader (VERSAmax Tunable 
Microplate Reader; Molecular Devices, CA, USA). The 
cell viability was expressed as the percentage of control 
using the following equation:
where “Abs (T)” is the absorbance of cells treated with 
DNPs and “Abs (C)” is the absorbance of the untreated 
cells.
Lactate dehydrogenase (LDH) leakage assay
Lactate dehydrogenase is a cytosolic enzyme present in 
live cells. In case of any damage to plasma membrane 
LDH is extruded into the media. Quantitative measure-
ment of LDH leakage provides an estimate of the cellu-
lar cytotoxicity caused due to loss of membrane integrity. 
LDH activity in the supernatant of the culture medium 
was determined using a commercial LDH based in vitro 
toxicology assay test (TOX-7, sigma). In short, 1 ×  104 




cells were seeded into each well of a 96-well cell culture 
plate containing 200  µl of complete growth medium. 
After 12 h of incubation at 37 °C temperature in 5 % CO2, 
cells were treated with threefold higher concentration i.e. 
50 µM of different DNPs and with DMSO as positive con-
trol. After 24  h treatment period, the culture plate was 
centrifuged in a swing bucket rotor at 250g for 5 min at 
37 °C. Fifty micro-liters of supernatant was taken in a 96 
well plate and mixed with equal volume of LDH mixture 
and incubated at room temperature for 30 min. Quantifi-
cation of the LDH release into the media was performed 
by measuring the absorbance at 490 nm.
Haemolysis assay
Haemolysis assays were performed in heparinised whole 
blood (2.5 ml) obtained from a healthy male human vol-
unteer. The blood sample was centrifuged at 1000×g 
for 20  min at 37  °C, buffy coat (white blood cells) was 
removed and the packed cells were washed twice with 
sterile PBS. PBS was added to the RBCs to obtain 2  % 
haematocrit. One-hundred micro-liters of cell suspen-
sion was added to each well of a 96 well plate containing 
different concentrations of the DNPs. Negative con-
trol included 50  µl of PBS solutions added to 100  µl of 
cell suspension (as red blood cell do not lyse in isotonic 
condition) and 50  µl of 1  % Triton X-100 was added in 
another well as the positive control (as RBCs lyse in a 
hypotonic medium). Void DNPs of three different con-
centrations (10, 20 and 50 µM) were added to 100 µl of 
cell suspension. Samples were incubated at 37  °C for 
60 min. The reaction was stopped by addition of 50 µl of 
2.5  % glutaraldehyde. Blood samples were then centri-
fuged at 1000×g for 15 min at 37 °C and the absorbance 
of the supernatant was measured at 540 nm using UV–
Vis spectrometer. The percentage haemolysis was calcu-
lated using the following equation:
where “Ts” is the absorbance of RBC treated with differ-
ent concentrations of DNPs and PBS. Whereas “Pc” is the 
absorbance of RBC treated with 1 % Triton X-100.
Loading of Ccm in DNPs
Loading is the most important benchmark for measur-
ing the nanoparticle efficacy as a drug delivery vehicle. 
Following the formation of nanoparticles (as discussed 
above), Ccm was loaded on to the DNPs by follow-
ing post loading method. Briefly, Ccm was added to 
the DNPs from a stock solution of the drug (10  mg/ml 
in methanol), at three different concentrations i.e. 1, 2 
and 3  mg/ml of the DNPs and incubated at room tem-
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drug formulations were further processed by ultrasonica-
tion for three minutes using sonication probe to remove 
any large aggregates formed. The nanoparticle disper-
sions were washed twice with filtered deionized water by 
centrifuging at 600×g for 30  min at room temperature, 
shock-frozen in liquid nitrogen and lyophilised at 0.40 m 
bar and −80  °C for 24  h using freeze dryer. The lyoph-
ilised powder was then resuspended in 1 mg/ml filtered 
deionized water and characterised using DLS and TEM. 
To determine the percentage loading capacity (LC) of 
Ccm in the DNPs, we employed methods described in 
previous studies [36]. In brief, lyophilized Ccm-loaded 
DNPs were dissolved in 1  ml of methanol. The samples 
were then centrifuged at 3300g for 30 min at room tem-
perature. The amount of Ccm in the supernatant was 
determined at 425  nm using V–Vis spectrophotometer. 
Calibration curve was generated using the reference 
standard and the loading capacity was determined as 
follows.
where Wnp refers to the total weight of Ccm in the 
nanoparticles; Wad the weight of Ccm added to the 
nanoparticles and Wdp the total dipeptide weight in the 
formulation.
In vitro Ccm release
An In vitro release study of Ccm was performed to moni-
tor the Ccm release profile at different time points using 
dialysis bags (MWCO: 3000) with floater (Spectrum Lab-
oratories, CA, USA). Briefly, lyophilised Ccm-FΔF nano-
particles (Stored for different time points day1, 14 and 
90) equivalent to 1 mg of Ccm, was dispersed in 1X PBS 
and filled in a dialysis bag, stirred at 100  rpm at 37  °C, 
under sink condition in 250  ml of 1:1 methanol: water, 
due to higher solubility of Ccm in this solvent mixture. At 
different time points (0.5, 1, 2, 4, 6, 12, 24, 48, and 96 h) 
1 ml of receptor medium was removed and replaced with 
same volume of fresh medium to maintain the total vol-
ume of release medium. To estimate Ccm release, 1 ml of 
receptor medium was lyophilised, resuspended in metha-
nol and quantified using (UV–Vis) spectrophotometer at 
a wavelength of 425 nm.
Long term stability of Ccm loaded FΔF (Ccm‑FΔF)
Long term stability of Ccm-FΔF was analyzed by a FEI 
Tecnai TEM at 120 kV (FEI Europe, The Netherlands) at 
different (1, 7th, 14th, 28th and 56th and 90th day) time 
points after negative staining with uranyl acetate (1 % in 
MQ water). Nanoformulations were prepared and lyoph-
ilised as described above, resuspended in PBS and stored 
at room temperature, to evaluate the long term stability. 
On completion of different time points (1, 7th, 14th, 28th 





and 56th and 90th day) Ccm-FΔF were adsorbed on 200 
mesh 3  mm carbon supported nickel grids and stained 
for 30  s with 1  % uranyl acetate and viewed under the 
electron microscope. Photomicrographs were digitally 
recorded using a Megaview II (SIS, Germany) digital 
camera. Image analysis to measure tube dimensions was 
carried out using Analysis II (Megaview, SIS, Germany) 
software package.
Photophysical properties of Ccm and Ccm content 
in Ccm‑FΔF
To determine whether entrapment in DNPs had any 
effect on Ccm’s photophysical properties after a long 
term storage of 90 days at room temperature (25 ± 2 °C), 
fluorescence spectra of Ccm-FΔF were taken at different 
time points (day 1 and 90) and compared with that of free 
Ccm. Fluorescence spectra of both native Ccm and Ccm-
FΔF at a concentration of 1 mg/ml were measured in an 
aqueous solution of methanol (1:1 v/v, methanol: water). 
Fluorescence emission spectra were recorded from 480 
to 650 nm with an excitation wavelength of 425 nm (LS 
55; Perkin Elmer). To determine the stability of Ccm in 
the nanoparticles without any leakage, total Ccm content 
in the DNPs was checked at different time points (day 1, 
14 and 90). This was carried out by dissolving 100 µg of 
Ccm-FΔF in 500 µl of methanol and then recording the 
absorption spectra at 425 nm using a microplate reader 
(VERSA max Tunable Microplate Reader; Molecu-
lar Devices, CA, USA). Ccm content was determined 
by comparing the sample with Ccm standard curve in 
methanol.
In vitro anti‑malarial activity of Ccm‑FΔF
Chloroquine resistant P. falciparum INDO strain was 
used for growth inhibition assays. Parasites were grown 
under in  vitro conditions by the method of Trager and 
Jensen with minor modifications [58]. In short, para-
site cultures were maintained in fresh O+ human eryth-
rocytes with 4  % hematocrit in complete RPMI1640 
medium (RPMI 1640 with 0.2  % sodium bicarbonate, 
0.5 % Albumax, 45 mg/l, hypoxanthine and 50 mg/l gen-
tamicin) at 37 °C under reduced O2 (gas mixture of 5 % 
O2, 5 % CO2, and 90 % N2). Ccm, curcumin loaded FΔF 
(Ccm-FΔF) and FΔF stocks were prepared in filtered 
sterile water. The stocks were diluted to get final assay 
concentrations (0–40 µM/100 µl of complete media) and 
transferred to sterile 96-well flat-bottom tissue culture 
grade plates. Plasmodium cultures were synchronized at 
ring stage by 5 % sorbitol solution. Synchronized culture 
was transferred to drug containing 96-well plates at 2 % 
hematocrit and 1  % parasitemia. Plasmodium growth 
inhibition was measured by carrying out high through-
put fluorescence based SYBR Green I assay. After 48 h of 
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incubation the fluorescence of the samples were deter-
mined using a 96-well fluorescence plate reader (Victor, 
Perkin Elmer), with excitation and emission wavelengths 
at 485 and 530 nm, respectively. The fluorescence read-




The rodent malarial parasite, P. berghei ANKA strain was 
maintained in BALB/c mice by weekly passage of infected 
blood containing 1 × 105 parasites intraperitonially (i.p.).
Animal model
Male mice (BALB/c), 4–6  weeks old, weighing 18–20  g 
were housed in the animal maintenance facility of Inter-
national Centre of Genetic Engineering and Biotechnol-
ogy, New Delhi, India. Animal experiments were approved 
by the Institutional Animal Care and Use Committee and 
animals were housed for a week for acclimatization in 
groups of five in the animal house. The animals were fed 
on commercial pellet diet and water ad  libitum in glass 
bottles. They were maintained under standard conditions 
of humidity (55–60 %), temperature (22 ± 3 °C) and light 
(12:12 h light/dark cycles). Animals used in this study were 
healthy and did not show any pathological symptoms.
In vivo anti‑malarial activity
Malaria was induced in BALB/c mice (with 18–20  g 
body weight) through blood transfusion. ANKA strain 
of P.bergi red blood cells (pRBC) were taken from an 
infected donor BALB/c mouse (10  % parasitimia) and 
diluted in PBS to 5 × 107pRBC/ml. Mice were infected 
intraperitoneal with an aliquot of 0.2  ml of this sus-
pension. Mice were then randomly divided into four 
groups with five mice in each group. Group I: P. berghei 
infection with PBS treatment; Group II: P. berghei 
infection and FΔF treatment; Group III: P. berghei infec-
tion and treatment with Ccm-FΔF (actual Ccm con-
tent was 50  mg/kg body weight); Group IV: P. berghei 
infection and Ccm treatment (50  mg/kg body weight). 
After reaching paracitemia 1–2  %, mice were treated 
for four successive days by intraperitoneal injection. 
Blood smears were prepared every alternate day from 
the tail vein for the period of 26 days (Fig. 9). Animals 
were kept under daily supervision for clinical signs and 
weight loss.
Measurement of parasitemia
Measurement of parasitemia was carried out after giemsa 
staining of parasites followed by microscopic imaging 
under oil immersion objective at 100× magnification. 
The percentage of infected erythrocytes was calculated in 
the fields of 1000 erythrocytes.
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